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Abstract
Background: Herbal products obtained over the counter are commonly used in Europe, North America and Australia.
Although there is concern about a lack of information provided to consumers to allow the safe use of these products,
there has been no published research to confirm these fears. In this study, we evaluated written information provided
with commonly used herbal products in the UK in advance of a European Union Directive issued in April 2011 that
tightened regulations for some herbal products, including requirements to provide safety information.
Methods: Five commonly used herbal products were purchased from pharmacies, health food shops and
supermarkets: St John’s wort, Asian ginseng, echinacea, garlic and ginkgo. Written information provided with the
products (on the package or on a leaflet contained in the package) was evaluated for inclusion of each of the key
safety messages included in the monographs of the US National Center for Complementary and Alternative
Medicine. Specifically, we looked for information on precautions (such as Asian ginseng not being suitable for
people with diabetes), interactions with conventional medicines (such as St John’s wort with the contraceptive pill
and warfarin) and side effects (such as ginkgo and allergic reactions).
Results: Our analysis showed that, overall, 51 (75%) of 68 products contained none of the key safety messages.
This included 4 of 12 St John’s wort products, 12 of 12 ginkgo products, 6 of 7 Asian ginseng products, 20 of 21
garlic products and 9 of 13 echinacea products. The two products purchased that are registered under the new
European Union regulations (for St John’s wort) contained at least 85% of the safety messages.
Conclusions: Most of the herbal medicine products studied did not provide key safety information which
consumers need for their safe use. The new European Union legislation should ensure that St John’s wort and
echinacea products will include the previously missing information in due course. The legislation does not apply to
existing stock. Depending on therapeutic claims made by manufacturers, garlic, ginkgo and Asian ginseng products
may not be covered by the legislation and can continue to be bought without the safety information. Also,
consumers will still be able to buy products over the internet from locations outside European Union jurisdiction.
Potential purchasers need to know, in both the short term and the long term, how to purchase herbal products
which provide the information they need for the safe use of these products.
Background
Complementary and alternative medicines (CAM) are
now mainstream in the UK and the rest of Europe, as
well as in North America and Australia [1-4]. Consu-
mers of herbal products available over the counter need
access to reliable and readily accessible information to
ensure their safe and appropriate use. The written infor-
mation people get when they buy herbal products is
particularly important because, although research in this
area is sparse, it has been shown that in the UK staff
knowledge about the products sold in community phar-
macies and health food shops can be lacking [5].
Research carried out for the UK medicines regulator,
the Medicines and Healthcare products Regulatory
Agency (MHRA) [1], found that many people believe
that herbal products are safe because they are natural,
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confirming previous findings [6,7], and that patients
often refrain from telling their physicians if they are
using an herbal product. Equally important is that few
doctors ask patients about their use of CAM, including
herbal products [8].
Many herbal products have adverse effects that are not
acknowledged or known by their users, with about one-
third being unaware of any possible risks [9]. In addi-
tion, most healthcare professionals believe that the pub-
lic is poorly informed about herbal products [10]. A
report by the MHRA [11] stated, ’With typical western
herbal medicine e.g. found in health food shops super-
markets etc the most frequent area of concern in the
unlicensed sector is lack of systematic patient informa-
tion’ (p. 6).
The need for reliable information is one of four points
highlighted in the World Health Organisation (WHO)
Traditional Medicines Strategy of 2002 [12]. In addition,
a WHO World Health Assembly resolution issued in
2003 urged member states to provide reliable informa-
tion to consumers to promote proper use of CAM.
Key pieces of information about the safe use of herbal
products that consumers need to know include (1) pre-
cautions, because many herbal products can be unsafe
for use by people with some preexisting illnesses, for
example, the use of Asian ginseng by people with dia-
betes; (2) interactions with other products, for example,
the use of St John’s wort affecting the efficacy of the
contraceptive pill or warfarin; and (3) adverse effects, for
example, allergic reactions associated with the use of
ginkgo [13]. Without such information, it will be more
difficult for the consumer to be able to make an
informed choice whether to use CAM, with possible
consequent adverse effects.
In some European countries, the use of herbal reme-
dies is widespread and well established [14]. Other
countries have a historical tradition of using herbal
medicines, such as the UK [15], and in other European
countries there are existing regulations for CAM (for
example, Austria and Germany [3]). Until 2011 in the
UK, there were three possible regulatory routes by
which an herbal product could reach a consumer. The
most common route was an unlicensed herbal remedy,
which does not have to meet specific standards of safety
and quality and is not required to be accompanied by
safety information for the consumer [11]. To help the
public make informed choices about the use of herbal
products, a European Union (EU) directive was imple-
mented in April 2011 after a seven-year transition per-
iod. The goal of this directive is to harmonise the
regulation of traditional herbal medicine products across
the EU and to establish a simplified licensing system
[16]. It requires that all manufactured herbal products
either gain a product licence of the type needed to
manufacture ‘conventional’ products or become regis-
tered as a ‘traditional herbal medicinal product’.
Licensed herbal medicines
Licensed herbal medicines hold a product licence, as do
conventional medicines (that is, based on safety, quality
and efficacy), and must be accompanied by comprehen-
sive information for the patient regarding their safe use.
This information comprises six categories: indications,
precautions, how to use the product, side effects, how to
store the product and regulatory information, all of
which are usually provided on a leaflet inserted into the
product package [17]. In addition, the leaflets have to be
tested with lay people to ensure that they are clear and
understandable [18]. However, it is widely recognised
that, although there is some evidence of efficacy for
some herbal medicines, evidence of reproducible efficacy
in many cases is currently insufficient to meet regulatory
standards. Hence a licence to sell these products cannot
be obtained.
Registered traditional herbal medicine
The new category of Traditional Herbal Registration
(THR) was created in April 2004 with a transition per-
iod of seven years [19]. As a result, in the UK, a ‘simpli-
fied registration scheme’, the Traditional Herbal
Medicines Registration Scheme, was introduced. In this
scheme, herbal medicine products have been required to
meet specific standards of safety and quality, have
agreed-upon indications for use based on their tradi-
tional use and include information for the purchaser to
promote the safe use of the product, which is provided
to the consumer in the form of a leaflet similar to that
required for licensed products [17]. The resulting dead-
line was 30 April 2011.
We found no previous studies on patient information
supplied with herbal products available for purchase in
the UK. Building on previous work describing consumer
information provided with conventional medicines [20],
we aimed to evaluate the information provided with a
select set of common herbal products available for pur-
chase in the UK. The objective was to ascertain whether
the products contained the minimum information
required to enable their safe use.
Methods
Study design
We conducted a cross-sectional survey involving content
analysis of written information provided with five com-
monly used herbal products: St John’s wort, garlic,
ginkgo, Asian ginseng and echinacea. These herbal pro-
ducts were chosen because one or more of the following
factors applied to each of them: evidence of interaction
between herbal medicine and a prescribed medicine
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[21], a risk-benefit profile had been undertaken [22] and
availability in retail outlets in local shopping areas. We
chose to include single-ingredient products intended for
oral use. We excluded products available as creams,
liquids, oils, sprays, teas and tinctures.
Obtaining the products
In the UK, herbal remedies are available in health food
shops and mainstream outlets such as pharmacies and
supermarkets [23,24]. Hence we bought all of the oral
use products containing one of the five herbal products
from three types of retail establishment in one city. The
sources were (1) two health food stores, Holland and
Barrett (the largest UK retail chain in this sector), and
an independent health food store associated with the
National Association of Health Food Stores; (2) three
pharmacies based in supermarkets (Tesco, Sainsbury’s
and Asda); and three large chain pharmacies (Boots,
Superdrug and Lloyds Chemists).
Evaluation criteria
We evaluated the information that accompanies each
product for completeness and accuracy in the key
safety areas of precautions, interactions and side
effects. The assessment of the completeness and accu-
racy of the information was not straightforward.
There is no single, recognised, authoritative source of
information on herbal medicines. Reference texts for
herbal medicines include Barnes et al. [25], the Nat-
ural Medicines Comprehensive Database [26], Mills
and Bone [27], Blumenthal et al. [28], the European
Medicines Agency [29] and the US National Center
for Complementary and Alternative Medicine
(NCCAM) [13].
However, no single text appears to be regarded as the
gold standard. In addition, the evidence basis for some
precautions, interactions and side effects is limited, and
sometimes there is no consensus regarding what these
are and their level of significance.
As this study was a general exercise designed to
broadly determine the appropriateness of information
provided with herbal medicine products, we chose to
base it on data contained in a free access resource con-
taining the most important and widely accepted safety
information. The Community Herbal Monographs pub-
lished online by the European Medicines Agency [29]
did not cover all five herbal medicine preparations.
However, they are all covered by the monographs pro-
duced by the NCCAM [13], which were therefore cho-
sen. NCCAM is part of the US National Institutes of
Health, and one of its roles is “disseminating authorita-
tive information to the public and professionals”. The
monographs are short (two pages) and contain only the
most important information and warnings.
Each monograph was analysed for content to identify
information related to precautions, interactions and side
effects. Analysis of the NCCAM monographs yielded 16
points of information for St John’s wort, 11 for ginkgo,
8 for garlic and for Asian ginseng, and 6 for echinacea
(Table 1).
We then performed a structured content analysis of
the information supplied with each of the purchased
products on the outer and inner packaging and any leaf-
let contained within the package. Each piece of informa-
tion was marked as being ‘present and accurate’ or
‘inaccurate or absent’. We marked information as cor-
rect if it broadly described the information correctly.
For example, where the interacting medicine was
digoxin, a leaflet description of ‘some products for heart
disease’ was deemed to be accurate.
Data extraction and quality assurance
All of the textual information on each product container
(and leaflet, if present) was photocopied so that we
could create a master copy of the information supplied
with each product. This information was then examined
by one researcher (RD), and the presence or absence of
each point of information was entered into a Microsoft
Excel database (Microsoft, Redmond, WA, USA). The
nine products supplied with an information leaflet were
also assessed by a second researcher (DKR). A check of
a randomly selected 10% of the products with informa-
tion on the package only was independently conducted
(DKR). Any differences were resolved by discussion to
reach consensus.
Results
Nature of the products
We found 68 products sold by 8 different retailers
which met the inclusion criteria: garlic, 21; St John’s
wort, 15; echinacea, 13; ginkgo, 12; and Asian ginseng, 7.
Regulatory category
The great majority (93%) of products were unlicensed.
Of these, 48 stated that they were food supplements.
The rest had no classification stated, so the actual pro-
duct classification could only be determined on a case-
by-case basis by the regulator. It is likely that a number
of products were supplied as unlicensed herbal medi-
cines under the Medicines Act 1968. The remaining five
products (7%) had either a product licence or THR. The
breakdown of the herbal products was as follows: unli-
censed, 63; THR, 2; and licensed product, 3.
Information provided
Among the 68 products, 59 (87%) of the manufacturers
provided information on the package and/or on the
label only, and nine also provided a leaflet package
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insert. The latter nine products were St John’s wort (4
of 15), echinacea (3 of 13) and garlic (2 of 21). Each of
the products with a product licence (n = 3) or THR (n
= 2) had a leaflet, but the remainder were unlicensed.
One of these leaflets mostly contained information pro-
moting other products. However, as the leaflet con-
tained some brief information on the herbal medicine
concerned, it was included.
Key points of safety information
Tables 2, 3, 4, 5 and 6 list each product by the number
allocated to it in this study (’study number’), its legal
category (where stated on the product), whether a leaflet
was supplied with the product and the number of safety
messages included (sub-divided into ‘Precautions’, ‘Inter-
actions’ and ‘Side effects’). The two products with THR
both contained 14 of 16 of the points of information.
Table 1 Key safety issuesa
St John’s wort Ginkgo Asian ginseng Garlic Echinacea
Precautions
Sensitivity to
sunlight
Increased bleeding
risk
People with diabetes should use extra caution,
especially if using medicines to lower blood sugar or
taking other herbs ... also thought to lower blood
sugar.
Can thin the blood Allergy to related plants in
daisy family
Bleeding disorders Use with caution if
planning to have
surgery or dental work.
People with asthma or
atopy may be more likely to
have an allergic reaction.
Scheduled surgery
or dental
procedures
Use with caution if you
have a bleeding
disorder.
Interactions
Antidepressants Anticoagulant
drugs
Interferes with
effectiveness of
saquinavir, a drug used
to treat HIV
Oral
contraceptives
Digoxin
Indinavir and
possibly other
HIV medications
Irinotecan and
possibly other
anticancer drugs
Seizure control
drugs
Warfarin and
related
anticoagulants
Cyclosporine
Side effects
Anxiety Headache Headache Breath and body odour Allergic reactions including
rashes
Dry mouth Nausea Sleep problems Heartburn Increased asthma
Dizziness Gastrointestinal
upset
Gastrointestinal problems Upset stomach Anaphylaxis
Gastrointestinal
symptoms
Diarrhoea Allergic reactions Allergic reactions Gastrointestinal side effects
Fatigue Dizziness Breast tenderness
Headache Allergic skin
reactions
Menstrual irregularities
Sexual
dysfunction
More severe
allergic reactions
occasionally
reported
High blood pressure
aAs identified in the NCCAM Herbs at a Glance monographs [13].
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Table 7 lists the number of products which contained
none of the points of information.
Discussion
The public should be able to expect full disclosure of
key safety information when they purchase products
herbal medicines over the counter [16]. This study has
shown that, among five herbal products commonly pur-
chased over the counter in the UK, most contained little
or no information regarding what to check for in order
to avoid harm before using the product. Three-quarters
of the preparations contained no safety information, and
only three contained most or all of the points of infor-
mation studied. For St John’s wort, which has generated
the most publicity regarding safe use, two-thirds of the
preparations failed to mention any of the possible inter-
actions with conventional medicines such as the oral
contraceptive or warfarin. This is consistent with the
findings of Clauson et al. [30] in the USA, where the
manufacturers of the vast majority of St John’s wort pre-
parations failed to adequately address clinically relevant
safety issues.
This study provides evidence supporting the need to
strengthen regulation of herbal medicines in the EU
[23]. Our results show that where a product (here, St
John’s wort) was registered as a THR, over 85% of the
safety information studied was included in the informa-
tion for the consumer. That this figure was not 100%
reflects, as stated above, the lack of consensus on the
safety information associated with individual herbal
medicines. The information provided with these THR
products reflects the MHRA’s assessment and is consis-
tent with data in the European Medicines Agency’s
Community Herbal Monographs [29].
The number of THR remains small; in this study, the
majority of products were not registered, and by April
2011 the MHRA had received 211 applications for THR,
among which 104 applications had so far been granted
and the remainder were under assessment (R Woodfield,
personal communication).
The introduction of the THR regulations in the UK in
April 2011 does not mean, however, that the issues
highlighted by this research will be fully resolved. First,
although most products containing either St John’s wort
or echinacea are likely to be classified as medicinal pro-
ducts (and hence their manufacturers will be required to
provide comprehensive information to the patient), the
position of garlic, ginkgo and ginseng is less clear.
Those products which make no claims to treat or pre-
vent disease will fall outside the regulatory remit (R
Woodfield, personal communication). Second, although
unregulated products should no longer be entering the
supply chain, stock already legally held by retailers can
continue to be sold, although this will be a time-limited
issue. Finally, there is a continuing likelihood of internet
availability of products from manufacturers and suppli-
ers in countries outside the jurisdiction of the MHRA.
Printing herbal medicine product information for the
consumer on the outside of the package is important to
enabling its safe use. Cramer et al. [5] point to a contin-
ued lack of knowledge among pharmacy staff about her-
bal products available in pharmacies. Furthermore,
Table 2 St John’s worta
Study number 1 2 3 4 67 70 72 75 30 31 32 41 48 58 61
Where bought HF HF HF HF HF HF HF HF Ph Ph Ph Ph Ph SM SM
Legal category U U U THR U U U U U THR U U U U U
Leaflet supplied? No No No Yes No No No No No Yes Yes No Yes No No
Precautions, n = 1 1 0 1 1 0 0 0 1 1 1 1 0 1 0 1
Interactions, n = 8 0 0 0 8 0 0 0 0 7 8 7 0 7 0 0
Side effects, n = 7 0 0 0 5 0 0 0 0 0 5 0 0 0 0 0
aHF = health food shop, Ph = pharmacy, SM = supermarket, U = unlicensed, THR = traditional herbal registration, PL = product licence. Each product is listed by
study number, where St John’s wort was bought, legal category, whether a leaflet was supplied and the number of safety messages (under ‘Precautions’,
‘Interactions’ and ‘Side effects’).
Table 3 Ginkgoa
Study number 5 6 7 8 73 33 34 35 36 42 56 64
Where bought HF HF HF HF HF Ph Ph Ph Ph Ph SM SM
Legal category U U U U U U U U U U U U
Leaflet
supplied?
No No No No No No No No No No No No
Precautions, n
= 4
0 0 0 0 0 0 0 0 0 0 0 0
Side effects, n
= 7
0 0 0 0 0 0 0 0 0 0 0 0
aHF = health food shop, Ph = pharmacy, SM = supermarket, U = unlicensed.
Table 4 Asian ginsenga
Study number 9 10 12 15 76 55 60
Where bought HF HF HF HF HF SM SM
Legal category U U U U U U U
Leaflet supplied? No No No No No No No
Precautions, n = 1 0 0 1 0 0 0 0
Side effects, n = 7 0 0 0 0 0 0 0
aHF = health food shop, SM = supermarket, U = unlicensed.
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although research evidence from health food shops was
limited, the advice offered there also appears to be var-
ied and inconsistent. Importantly, Cramer and collea-
gues found that a significant majority of people who buy
herbal products need help in selecting an appropriate
product. Others have recognised that pharmacists lack
training and knowledge regarding herbal remedies [31].
Most pharmacy customers in an Australian study
thought pharmacists should provide safety information
about herbal products [4], and in Canada, most consu-
mers and pharmacists thought pharmacists should be
knowledgeable about natural health products and able
to manage possible drug interactions [32].
In addition to the general need for the public to be
educated about the safe use of herbal products and
know where to find good information about them, there
is a related issue about patients telling their healthcare
providers about their herbal product use. There appears
to be a general reluctance of patients to tell this to their
physicians, with one UK study finding that a large
majority did not tell their general practitioners about
their use of herbal products [33]. Consumers should be
encouraged to tell their healthcare practitioners about
any use of herbal products, and practitioners should
consider initiating such discussions [34]. This does not,
however, take away the necessity for accurate and com-
plete written information about precautions, interactions
and side effects to be provided to consumers when they
buy herbal products.
The most commonly discussed safety problems asso-
ciated with the use of herbal products relate to interac-
tions with medicine prescribed by a conventional
biomedical practitioner. We know that the use of over-
the-counter herbal products concomitantly with conven-
tional medicines is widespread and that there are
numerous possible interactions [21]. In a study of cardi-
ology patients, among the herbal products singled out,
all five included in the present study were described as
being especially dangerous in elderly patients [35]. A
UK survey of health professionals found that 86% think
the public is poorly informed about herbal products,
with the main reason for concern being potential inter-
actions with traditional medicines [10].
Apart from the information provided on or in the her-
bal product package, what other sources do people use
to find out about herbal products? Cramer et al. [5]
found that pharmacy customers accessed information
from CAM practitioners, friends and family, books,
newspapers, magazines and the internet. However, reli-
able and readily accessible information sources on her-
bal medicines are limited [36]. A survey focussing on
ginseng, ginkgo and St John’s wort found that among
150 websites, 25% contained statements that could
cause harm to users of these herbal products and 97%
had omitted information [37].
Conclusions
It is clear that consumers are entitled to better informa-
tion with the CAM that they buy, so that they are aware
of any safety issues and to enable them to make
informed decisions [7]. Just as for conventional
Table 5 Garlica
Study number 19 20 21 22 23 24 25 26 69 71 74 43 49 50 52 53 54 45 46 59 62
Where bought HF HF HF HF HF HF HF HF HF HF HF Ph Ph Ph Ph Ph Ph SM SM SM SM
Legal category U U U U U U U U U U U U U U U U U U U U U
Leaflet supplied? No No No No Yes No No No No No No No No No No No Yes No No No No
Precautions, n = 4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
Side effects, n = 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
aHF = health food shop, Ph = pharmacy, SM = supermarket, U = unlicensed.
Table 6 Echinacea
Study
number
66 68 77 16 17 37 38 39 40 47 57 44 63
Bought
from
HF HF HF HF HF Ph Ph Ph Ph Ph SM SM SM
Legal
category
U U U PL U PL U U U PL U U U
Leaflet
supplied?
No No No Yes No Yes No No No Yes No No No
Precautions,
n = 2
0 0 1 0 1 0 0 0 0 0 0 0 0
Side effects,
n = 4
0 0 0 1 0 1 0 0 0 0 0 0 0
aHF = health food shop, Ph = pharmacy, SM = supermarket, U = unlicensed,
PL = product licence.
Table 7 Presence or absence of information points for
each category of herbal product
Herbal product Some points of
information
No points of
information
St John’s wort, n = 15 (%) 11 (73%) 4 (27%)
Ginkgo, n = 12 (%) 0 (0%) 12 (100%)
Asian ginseng, n = 7 (%) 1 (14%) 6 (86%)
Garlic, n = 21 (%) 1 (5%) 20 (95%)
Echinacea, n = 13 (%) 4 (31%) 9 (69%)
Total, n = 68 (%) 17 (25%) 51 (75%)
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medicines, this is important for herbal products as well,
because harm to the consumer is possible when such
information is not available. The 2011 EU legislation
will ensure that such information is available for many
products, but products not classified as medicinal pro-
ducts will escape the net of regulation. Also, existing
stock will continue to be legally available for a period
and internet purchases from sources outside the EU will
not be covered. This means that consumers need to be
advised where and how to purchase herbal products so
that the necessary information for safe use will be avail-
able to them. They should look for products registered
as THR and seek outlets where staff might be antici-
pated to have knowledge of and training in the safe use
of herbal products. In addition, there should be ongoing
monitoring of the written information supplied with
these products to encourage improvements in this
important safety issue.
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